Inhibition of prolyl 4-hydroxylase prevents left ventricular remodelling in rats with thoracic aortic banding

European Journal of Heart Failure

Volumn 9, Issue 4, 2007, Pages 336-342

  Fielitz, Jens ^a   Philipp, Sebastian ^c,e   Herda, Lars Roman ^a   Schuch, Evelyn ^a   Pilz, Bernhard ^c   Schubert, Carola ^a   Günzler, Volkmar ^d   Willenbrock, Roland ^c,f   Regitz Zagrosek, Vera ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

^d FIBROGEN INC   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Krankenhaus St Elisabeth und St Barbara   (Germany)

Author keywords

Aortic banding; Growth factors; Hypertrophy; Prolyl 4 hydroxylase; Remodelling

Indexed keywords

COLLAGEN; ENDOTHELIN; GROWTH FACTOR; MATRIX METALLOPROTEINASE; NEUROHORMONE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ECHOCARDIOGRAPHY; EVALUATION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; COLLAGEN TYPE I; COLLAGEN TYPE III; FIBROSIS; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MYOCARDIUM; PROCOLLAGEN-PROLINE DIOXYGENASE; RATS; RATS, WISTAR; RISK FACTORS;

EID: 33947307148     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.10.006     Document Type: Article

References (30)

1. Verdecchia P., Carini G., Circo A., et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38 (2001) 1829-1835
2. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 (2001) 1615-1621
3. Frey N., Katus H.A., Olson E.N., et al. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
4. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003) 45-79
5. Hein S., Arnon E., Kostin S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107 (2003) 984-991
6. Boluyt M.O., O'Neill L., Meredith A.L., et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res 75 (1994) 23-32
7. Walther T., Schubert A., Falk V., et al. Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation 104 (2001) I54-I58
8. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
9. Lindsey M.L., Mann D.L., Entman M.L., et al. Extracellular matrix remodelling following myocardial injury. Ann Med 35 (2003) 316-326
10. Spinale F.G., Gunasinghe H., Sprunger P.D., et al. Extracellular degradative pathways in myocardial remodelling and progression to heart failure. J Card Fail 8 (2002) S332-S338
11. Iwanaga Y., Aoyama T., Kihara Y., et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodelling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 39 (2002) 1384-1391
12. Fielitz J., Hein S., Mitrovic V., et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 37 (2001) 1443-1449
13. Ruwhof C., and van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 47 (2000) 23-37
14. Balzac F., Belkin A.M., Koteliansky V.E., et al. Expression and functional analysis of a cytoplasmic domain variant of the beta 1 integrin subunit. J Cell Biol 121 (1993) 171-178
15. Hanks S.K., Calalb M.B., Harper M.C., et al. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A 89 (1992) 8487-8491
16. Lin T.H., Aplin A.E., Shen Y., et al. Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J Cell Biol 136 (1997) 1385-1395
17. Graf K., Do Y.S., Ashizawa N., et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 96 (1997) 3063-3071
18. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153 (1993) 937-942
19. Schunkert H., Orzechowski H.D., Bocker W., et al. The cardiac endothelin system in established pressure overload left ventricular hypertrophy. J Mol Med 77 (1999) 623-630
20. Sakai S., Miyauchi T., Sakurai T., et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93 (1996) 1214-1222
21. Nwogu J.I., Geenen D., Bean M., et al. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104 (2001) 2216-2221
22. Knecht M., Pagel I., Langenickel T., et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 71 (2002) 2701-2712
23. Ivan M., Haberberger T., Gervasi D.C., et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 99 (2002) 13459-13464
24. Hirsila M., Koivunen P., Gunzler V., et al. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278 (2003) 30772-30780
25. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
26. Philipp S., Pagel I., Hohnel K., et al. Regulation of caspase 3 and Fas in pressure overload-induced left ventricular dysfunction. Eur J Heart Fail 6 (2004) 845-851
27. Fielitz J., Dendorfer A., Pregla R., et al. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 105 (2002) 286-289
28. Fielitz J., Leuschner M., Zurbrugg H.R., et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 82 (2004) 809-820
29. Martinella-Catusse C., Polette M., Noel A., et al. Down-regulation of MT1-MMP expression by the alpha3 chain of type IV collagen inhibits bronchial tumor cell line invasion. Lab Invest 81 (2001) 167-175
30. Nakata K., Miyamoto S., Bernier S., et al. The c-propeptide of type II procollagen binds to the enhancer region of the type II procollagen gene and regulates its transcription. Ann N Y Acad Sci 785 (1996) 307-308